Quick Answer: Yes, GLP-1 receptor agonists effectively reduce visceral fat, as demonstrated by clinical trials using CT and MRI imaging showing significant decreases in visceral adipose tissue volume alongside improvements in waist circumference and cardiometabolic markers
Imeryz N, Yeen B, Bozkurt A, Cokun T, Villanueva-Penacarrillo ML, Ulusoy NB
The FDA boxed warning for thyroid C-cell tumors based on rodent studies applies to both semaglutide and tirzepatide regardless of whether the product is branded or compounded
What if Medicare doesnt cover Foundayo for you
Weve already discussed how important a good nutrition plan is
Older adults, those taking concurrent medications affecting gut motility, and individuals with slower metabolic rates may also show heightened responses